Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency
Open accessThe DOI matches its Crossref record.
Abstract
Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation caused by defective carnitine transport. This disease presents early in life with hypoketotic hypoglycemia or later in life with skeletal myopathy or cardiomyopathy. The gene for this condition maps to 5q31.2–32 and OCTN2, an organic cation/carnitine transporter, also maps to the same chromosomal region. Here we test the causative role of OCTN2 in primary carnitine deficiency by searching for mutations in this gene in affected patients. Fibroblasts from patients with primary carnitine deficiency lacked mediated carnitine transport. Transfection of patient’s fibroblasts with the OCTN2 cDNA partially restored carnitine transport. Sequencing of the OCTN2 gene revealed different mutations in two unrelated patients. The first patient was homozygous (and both parents heterozygous) for a single base pair substitution converting the codon for Arg-282 to a STOP codon (R282X). The second patient was a compound heterozygote for a paternal 1-bp insertion producing a STOP codon (Y401X) and a maternal 1-bp deletion that produced a frameshift creating a subsequent STOP codon (458X). These mutations decreased the levels of mature OCTN2 mRNA and resulted in nonfunctional transporters, confirming that defects in the organic cation/carnitine transporter OCTN2 are responsible for primary carnitine deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Heintzman, N. D., Stuart, R. K., Hon, G., Fu, Y., Ching, C. W., Hawkins, R. D., Barrera, L. O., Van Calcar, S., Qu, C., Ching, K. A., et al. (2007) · Nature Genetics · doi:10.1038/ng1966 · Cited by 3,398
Carnitine transport and fatty acid oxidation
Longo, N., Frigeni, M., & Pasquali, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.023 · Cited by 996
Self-citationKoepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Carnitine biosynthesis in mammals
Vaz, F. M., & Wanders, R. J. A. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3610417 · Cited by 764
Bedi, K. C., Snyder, N. W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A. J., Wang, L. L., Javaheri, A., Blair, I. A., Margulies, K. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017545 · Cited by 650
Flanagan, J. L., Simmons, P. A., Vehige, J., Willcox, M. D., & Garrett, Q. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-30 · Cited by 611
“Several mutations have been described [21,22,25,26,29,31-33].”
BackgroundDisorders of carnitine transport and the carnitine cycle
Longo, N., Amat di San Filippo, C., & Pasquali, M. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30087 · Cited by 543
“However, there is no correlation between genotype and clinical presentation [Scaglia et al., 1998; Wang et al., 1999, 2000a,b, 2001; Amat Di San Filippo and Longo, 2004; Dobrowolski et al., 2005].”
BackgroundSelf-citationCarnitine and Acylcarnitines: Pharmacokinetic, Pharmacological and Clinical Aspects
Reuter, S. E., & Evans, A. M. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261931 · Cited by 493
Cellular and molecular aspects of drug transport in the kidney
Inui, K.-I., Masuda, S., & Saito, H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00251.x · Cited by 450
Wu, X., Huang, W., Prasad, P. D., Seth, P., Rajan, D. P., Leibach, F. H., Chen, J., Conway, S. J., & Ganapathy, V. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35056-6 · Cited by 330
Self-citationRenal Transporters in Drug Development
Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L., & Giacomini, K. M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140317 · Cited by 324
The multispecific organic anion transporter (OAT) family
Sekine, T., Cha, S. H., & Endou, H. (2000) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240000297 · Cited by 323
Koepsell, H., Schmitt, B. M., & Gorboulev, V. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0017-x · Cited by 316
Pharmacokinetics of L-Carnitine
Evans, A. M., & Fornasini, G. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342110-00002 · Cited by 301
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Molecular and Functional Characterization of Organic Cation/Carnitine Transporter Family in Mice
Tamai, I., Ohashi, R., Nezu, J.-I., Sai, Y., Kobayashi, D., Oku, A., Shimane, M., & Tsuji, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005340200 · Cited by 292
β-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter
Ganapathy, M. E., Huang, W., Rajan, D. P., Carter, A. L., Sugawara, M., Iseki, K., Leibach, F. H., & Ganapathy, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.1699 · Cited by 175
Self-citationCarnitine transport: Pathophysiology and metabolism of known molecular defects
Tein, I. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024481016187 · Cited by 140
Wang, C., Uray, I. P., Mazumdar, A., Mayer, J. A., & Brown, P. H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1925-0 · Cited by 59
Jurkiewicz, D., Michalec, K., Skowronek, K., & Nałęcz, K. A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.02.014 · Cited by 15
Metadata
- Authors
- Wang, Y., Ye, J., Ganapathy, V., & Longo, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-03-02
- Volume
- 96
- Issue
- 5
- Pages
- 2356-2360
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2031054218
- Cited by
- 195
- References
- 0
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.